论文部分内容阅读
流行性脑脊髓膜炎(下称流脑)是一种严重危害儿童身体健康的急性呼吸道传染病,病死率高,尤以婴幼儿更为严重。自1969年Gotschlich等从脑膜炎双球菌提取大分子量多糖抗原成功地用于人群免疫以来,流脑的流行得到了很好的控制,国内外相继应用A、C群脑膜炎球菌多糖菌苗用于人群预防接种,其保护率达90％以上,但该菌苗对2岁以下婴幼儿免疫效果差,不能控制流脑发病。对此,已引起国内外研究者的重视。为提高婴幼儿免疫效果,
Epidemic cerebrospinal meningitis (hereinafter referred to as “meningitis”) is an acute respiratory disease that seriously endangers the health of children and has a high case fatality rate, especially for infants and toddlers. Since 1969, Gotschlich et al. Extracted meningococcal meningococcal polysaccharide antigen was successfully used in population immunization, the prevalence of meningitis has been well controlled at home and abroad have been using A, C meningococcal polysaccharide vaccine for Population vaccination, the protection rate of 90% or more, but the vaccine for infants under the age of 2 immune effect is poor, can not control the incidence of meningitis. In this regard, it has attracted the attention of researchers at home and abroad. To improve the immune effect of infants and young children,